Clinical trial NCT00558545 - References

Human Mammary Carcinoma — A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer

Citation(s)

•   Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU
  Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996 Aug;14(8):2197-205.
•   Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ
  Cancer statistics, 2006. CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30.
•   Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R
  Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2001 Nov 15;19(22):4216-23.
•   Seidman, A
  , et al., CALGB 9840: Phase III study of weekly paclitaxel via 1-hour infusion versus standard 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. Proc Am Soc Clin Oncol, 2004. 23: p. 6s.

A Phase 1-2, Multicenter, Open-Label Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer

Details for clinical trial NCT00558545